2024
Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression
Swanberg K, Prinsen H, Averill C, Campos L, Kurada A, Krystal J, Petrakis I, Averill L, Rothman D, Abdallah C, Juchem C. Medial prefrontal cortex neurotransmitter abnormalities in posttraumatic stress disorder with and without comorbidity to major depression. NMR In Biomedicine 2024, 37: e5220. PMID: 39054694, DOI: 10.1002/nbm.5220.Peer-Reviewed Original ResearchPosttraumatic stress disorderMedial prefrontal cortexStress disorderPosttraumatic stress disorder patientsPosttraumatic stress disorder diagnosisChronic psychiatric conditionImpact of psychiatric comorbiditiesComorbid MDDPrefrontal cortexDepressive disorderTraumatic stressorsPsychiatric conditionsMDDPsychiatric comorbiditiesNeurotransmitter abnormalitiesConcentrations of glutamateMetabolite abnormalitiesHealthy controlsDisordersPattern of abnormalitiesParticipantsGlutamateIn vivo protonMetabolic abnormalitiesDepression
2013
Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence
Ralevski E, Jane J, O’Brien E, Edens E, Arnaout B, Kerfoot K, Keegan K, Weiner J, Russo M, Petrakis I. Mecamylamine for Treatment of People With Dual Diagnoses of Depression and Alcohol Dependence. Journal Of Dual Diagnosis 2013, 9: 301-310. DOI: 10.1080/15504263.2013.835163.Peer-Reviewed Original ResearchDepressive symptomsAlcohol dependenceDual diagnosisRates of smokingMain outcome variablesSymptoms of depressionTreatment of peopleTreatment trialsComorbid depressionMecamylamineSide effectsNonsmokersSmokingSymptomsOutcome variablesBest treatmentDrinking outcomesDepressionPlaceboSmokersFurther studiesSignificant differencesDiagnosisParticipantsTreatment